Budding ASX Junior Pens Transformative Medical Cannabis Deals: Now Generating Revenue
Nov 23, 2017
MGC Pharmaceuticals (ASX:MXC) was the second company to originally emerge in the ASX cannabis corridor, and with a whip-smart team that’s put in serious hours in the industry-leading Israeli medicinal marijuana scene, this ASX junior is rapidly coming into its own.
Could One ASX Junior Have All the Elements to Crack $121BN Natural Skincare Market?
Nov 15, 2017
This Australian-based developer of US FDA and Australia TGA approved natural and organic skin care products already has mainstream reach spanning over 15 countries, through its 100% natural and organic sunscreen Soleo Organics and is set to launch its organics sunscreen range into the US$10BN global suncare market.
IMU Picks up the Pace in Cancer Drug Treatment Development
Aug 09, 2017
It is difficult to understate the possible impact of the immuno-oncology therapies that the $33 million-capped Imugene (ASX: IMU) is currently developing. These therapies, if proven safe and successful, could have an undeniable real world positive effect for cancer patients.
CPH Signs Exclusive Cannapharm deal: On Track for 2017 Product Release
Jun 14, 2017
News of $100 million IPOs, alongside an avalanche of parallel legislative changes around the world, builds a strong case for the burgeoning medicinal marijuana industry. With so many medicinal cannabis stocks fighting for market share and threatening to steal the limelight, a company such as Creso Pharma Ltd (ASX: CPH) needs to do all it can to stay current and competitive.
CPH Deliver Australia’s First Medicinal Cannabis Shipment Under New Legislation
May 02, 2017
Creso Pharma (ASX: CPH) has made a shipment of medicinal cannabis into Australia – the first import into the country under new government legislation. Under an agreement between CPH and its Australian partner, Health House International Pty Ltd, the pair will distribute a range of cannabis oil products across Australian pharmacies, in compliance with Federal and State legislation.
Beating Cancer via Early Detection: ASX Stock Targeting Multiple Billion Dollar Markets
Apr 04, 2017
If you are going to beat cancer, your best bet is to catch it early. Of course, that’s easier said than done. By the time the symptoms of many cancers are apparent, a patient is often already in late stages of the disease. This is particularly true for lung cancer.
ASX Stock to Launch on NASDAQ with Gut Busting Immunotherapy Products
Mar 24, 2017
Today’s $30 million capped ASX listed biotech player, which is in the process of listing on the NASDAQ, has thus far flown right under the radar of Australia’s biotech landscape. This scenario is likely to change, however, as this cutting edge company has chosen to take aim at the oral immunotherapy sector, with antibody products […]
Medical Marijuana Stock CPH Plants First Seeds in $800M Brazilian Market
Mar 22, 2017
There is no doubt about it – medical marijuana stocks are lighting up the ASX right now, as the mainstream media and investment community at large is finally starting to pick up on what we have been saying for over 12 months now.
Could this ASX Cancer Therapy Junior Attract a Billion Dollar Big Pharma Deal?
Mar 16, 2017
One in every two Australians will be diagnosed with cancer by age 85. That’s a staggering statistic that has prompted a great deal of contemplation among doctors, patients and those affected in some way by the consequences of the disease. To try and combat the rise and spread of cancer, Big Pharma, along with smaller biotech companies are working on treatments and potential cures. One $30 million capped ASX junior may have a unique solution.
Strategic Cannabis Acquisition Complete: MXC Set to Break Ground in Europe, Australia the Next Step
Feb 23, 2017
In the case of MGC Pharmaceuticals (ASX: MXC), this ASX-dwelling green thumb is making a bee-line for the global medical cannabis market. This most recent move by the Australian government opens up several commercial channels for MXC with regard to its medical cannabis and cosmetics plays, given recent developments with its European operations.
CDY Backs Hair Raising Growth for 2017 as it Capitalises on US Entry
Jan 24, 2017
Volume is a key word for life sciences play Cellmid (ASX: CDY). Its key hair loss product Evolis® aims to replace thinning hair with voluminous locks, while management seeks to volumise revenues, stock liquidity, and ultimately shareholders’ returns.